Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)

Next Previous
Trial Profile

A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iluzanebart (Primary)
  • Indications Leukoencephalopathies
  • Focus Adverse reactions
  • Sponsors Vigil Neuroscience

Most Recent Events

  • 11 Jun 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: No beneficial effects on biomarker or clinical efficacy endpoints.
  • 22 May 2025 Planned End Date changed from 31 Mar 2027 to 31 Jan 2027.
  • 03 Dec 2024 Planned primary completion date changed from 31 Jul 2024 to 7 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top